MedTrace Logo

Coping Skills Training for Early Rheumatoid Arthritis

NCT00056394 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2018-10-25

No results posted yet for this study

Summary

Rheumatoid arthritis (RA) is the most common inflammatory arthritis and a major health problem. Medical treatments are now being used much earlier in the course of RA, but these treatments do not address the challenges of coping with the early stages of this disease. This study will determine whether a comprehensive coping skills training program can decrease pain, psychological disability, and physical disability in patients with early RA.

Conditions

Interventions

BEHAVIORAL

Comprehensive Coping Skills Training

10 weekly, 80-minute coping skills treatment sessions, followed by a series of six biweekly follow-up telephone calls.

BEHAVIORAL

Arthritis Education Sessions

10 weekly, 80-minute treatment sessions, followed by a series of six biweekly follow-up telephone calls. Participants will learn about the nature and treatment of rheumatoid arthritis as well as the benefits of exercise and joint protection.

BEHAVIORAL

Standard Care

Usual care from participants' rheumatologists but no treatment sessions.

Sponsors & Collaborators

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    collaborator NIH

  • Duke University

    lead OTHER

Principal Investigators

  • Francis J. Keefe, PhD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00056394 on ClinicalTrials.gov